Rational Computational Workflow for Structure-Guided Discovery of a Novel USP7 Inhibitor
- PMID: 40263111
- DOI: 10.1021/acs.jcim.4c01400
Rational Computational Workflow for Structure-Guided Discovery of a Novel USP7 Inhibitor
Abstract
Rationally applied, structurally guided computational methods hold the promise of identifying potent and distinct chemotypes while enabling the precise targeting of structural determinants. Here, we implemented a computational workflow combining insights from cocrystal poses and monitoring the dynamical structural determinants from our previous studies for the identification of potential candidates against USP7. We identified and tested several diverse chemical scaffolds, which underwent in vitro validation across six cancer cell lines. Among these hits, compound M15, belonging to the benzothiazole chemical class, exhibited remarkable anticancer activities, demonstrating dose-dependent reduction in cancer cell viability across all cell lines and indicating that it is a promising candidate to explore as a potent anticancer drug. Biophysical binding confirms binding of M15 on USP7. M15 also exhibited certain USP7 inhibitory activity, as observed in the enzymatic assay. A comparative cocrystal mining of reported USP7 inhibitors unveiled a distinct binding mode of M15, which nicely cross-corroborated with MD and binding-pose metadynamics simulations. Notably, M15 occupies both the determinants, i.e., BL1 and the allosteric checkpoint, which has not yet been underscored as a druggable site. In essence, our study presents a robust and multifaceted computational method for the discovery and characterization of a novel inhibitor scaffold, exemplified by the identification and mechanistic elucidation of M15 against USP7. This integrated approach not only advances our understanding of USP7 inhibition and underscores mechanistic determinants but also offers promising avenues for the discovery of target-specific therapeutic intervention.
Similar articles
-
An Integrated in silico Approach and in vitro Study for the Discovery of Small-Molecule USP7 Inhibitors as Potential Cancer Therapies.ChemMedChem. 2021 Feb 4;16(3):555-567. doi: 10.1002/cmdc.202000675. Epub 2020 Nov 12. ChemMedChem. 2021. PMID: 33063944
-
Beyond Docking: A Multitier Computational Pipeline for USP7 Inhibitor Optimization.ChemMedChem. 2025 Aug 16;20(16):e202500210. doi: 10.1002/cmdc.202500210. Epub 2025 Jun 16. ChemMedChem. 2025. PMID: 40289327 Free PMC article.
-
Stereo-selectivity of enantiomeric inhibitors to ubiquitin-specific protease 7 (USP7) dissected by molecular docking, molecular dynamics simulations, and binding free energy calculations.Mol Divers. 2025 Apr;29(2):1725-1735. doi: 10.1007/s11030-024-10948-z. Epub 2024 Sep 19. Mol Divers. 2025. PMID: 39298085
-
Ubiquitin-Specific Protease 7 (USP7) as a Promising Therapeutic Target for Drug Discovery: From Mechanisms to Therapies.J Med Chem. 2025 Apr 24;68(8):7914-7931. doi: 10.1021/acs.jmedchem.5c00102. Epub 2025 Apr 16. J Med Chem. 2025. PMID: 40237780 Review.
-
Chemical Approaches to Intervening in Ubiquitin Specific Protease 7 (USP7) Function for Oncology and Immune Oncology Therapies.J Med Chem. 2018 Jan 25;61(2):422-443. doi: 10.1021/acs.jmedchem.7b00498. Epub 2017 Aug 18. J Med Chem. 2018. PMID: 28768102 Review.
Cited by
-
Structural insights into Beclin 1 interactions with it's regulators for autophagy modulation.Comput Struct Biotechnol J. 2025 Jul 7;27:3005-3035. doi: 10.1016/j.csbj.2025.06.044. eCollection 2025. Comput Struct Biotechnol J. 2025. PMID: 40687997 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources